Cover

A Balanced Omega-6/Omega-3 Fatty Acid Ratio, Cholesterol and Coronary Heart Disease

Editor(s): Simopoulos A.P. (Washington, D.C.) 
De Meester F. (Waterloo, Ont.) 
Table of Contents
Vol. 100, No. , 2009
Section title: Paper

Disappointing Recent Cholesterol-Lowering Drug Trials: Is It Not Time for a Full Reappraisal of the Cholesterol Theory?

de Lorgeril M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kastelein JJ, Akdim F, Stroes ES: for ENHANCE investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
  2. Mitka M: Controversies surround heart drug study. Questions about Vytorin and trial sponsors’ conduct. JAMA 2008;299:885-887
  3. Greenland P: Lloyd-Jones D: Critical lessons from the ENHANCE trial. JAMA 2008;299:953-955
  4. O’ Riordan M: Congress continues to probe Merck and Shering-Plough: angry emails highlight ENHANCE controversy. http:www.medscape.com/viewarticle/572392
  5. Stevermer J, ENHANCE study: ezetimibe lowers LDL, but does it matter?. J Fam Pract 2008;57:436-437
  6. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation 1997;96:1432-1437
  7. O’Leary DH, Polak JF, Kronmal RA, et al: Carotid intima-media thickness as a risk factor of myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22
  8. Smilde TJ, van Wissen S, Wollersheim H, et al: Effect of aggressive versus conventional lipid-lowering on Atherosclerosis Progression in Familial Hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-581
  9. Taylor AJ, Kent SM, Flaherty PJ, et al: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima media thickness. Circulation 2002;106:2055-2060
  10. Toutouzas P, Richter D: Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial. Angiology 2008;59:77S-79S
  11. Stein EA: Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?. J Am Coll Cardiol 2008;52:2206-2209
  12. Sudhop T: von Bergmann K: Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs 2002;62:2333-2347
  13. O’Riordan M: JUPITER halted: rosuvastatin significantly reduces cardiovascular morbidity and mortality. From Heartwire, a professional news service available at:http://medscapemobile.com/viewarticle/572270
  14. AstraZeneca: Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit. http://www.astrazeneca.com/pressrelease/5385.aspx
  15. Knopp RH, d’Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-1485
  16. Wanner C, Krane V, März W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248
  17. Asselbergs FW, Diercks GFH, Hillege HL, et al: for the Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) investigators. Effect of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-2816
  18. Pedersen TR, Faergeman O, Kastelein JJ, et al: High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study, a randomized controlled trial. JAMA 2005;294:2437-2445
  19. Barter PJ, Caulfield M, Eriksson M, et al: for the ILLUMINATE investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122
  20. O’ Riordan M: CASHMERE: no IMT effect with atorvastatin over 12 months. http:www.medscape.com/viewarticle/577309
  21. O’ Riordan M: ACHIEVE stopped: IMT study with Niacin/Laropiprant halted by Merck & Co. http:www.medscape.com/viewarticle/574978
  22. Topol EJ: Failing the public health. Rofecoxib, Merck and the FDA. N Engl J Med 2004;315:1707-1709
  23. Bollapragada S, Norrie J, Norman J: Review of new regulations for the conduct of clinical trials of investigational medicinal products. BJOG 2007;114:917-921
  24. Chalmers I: Proposal to outlaw the term ‘negative trial’. BMJ 1985;290:1002
  25. Rossebø AB, Pedersen TR, Boman K, et al: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
  26. GISSI-HF Investigators: Tavazzi L, Maggioni AP, Marchioli R, et al: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239
  27. Palta S, Pai AM, Gill SK, Pai RG: New insights into the progression of aortic stenosis: implication for secondary prevention. Circulation 2000;101:2497-502
  28. Nassimiha D, Arronow WS, Ahn C, Goldman ME: Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001;87:1313-1314
  29. Mautner GC, Roberts WC: Reported frequency of coronary arterial narrowing by angiogram in patients with valvular aortic stenosis. Am J Cardiol 1992;70:539-540
  30. Peltier M, Trojette F, Sarano ME, et al: Relation between cardiovascular risk factors annd non rheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 2003;91:97-99
  31. Davidson MH: Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005;111:2280-2281
  32. Nissen JE: Courage under fire: what is the optimal approach to initial treatment of stable angina?. Curr Cardiol Rep 2008;10:79-80
  33. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080
  34. Cannon CB, Braunwald E, McCabe CH, et al: Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
  35. Peto R, Emberson J, Landray M, et al: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-1366
  36. Collins R, Peto R: Analyses of cancer data from three ezetimibe trials: the authors reply. N Engl J Med 2009;360:86-87
  37. Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261
  38. Khush KK, Waters D: Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Cleve Clin J Med 2004;71:609-616
  39. Scirica BM, Morrow DA, Cannon CP, et al: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-2331
  40. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718
  41. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44
  42. Ridker PM, Danielson E, Fonseca FA, et al: for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
  43. Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH: Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med 2007;146:878-881
  44. Montori VM, Devereaux PJ, Adhikari NK, et al: Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-2209
  45. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P: Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-1557


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00